Stock 4503 ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Astellas Pharma Inc. Stock

Equities

4503

JP3942400007

Pharmaceuticals

Delayed Japan Exchange
Other stock markets
 08:35:11 2024-04-24 pm EDT 		5-day change 1st Jan Change
1,466 JPY -0.20% Intraday chart for Astellas Pharma Inc. +0.03% -13.05%
02:49am European Commission Approves Astellas Pharma Label Extension for Xtandi MT
Apr. 22 Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs MT

Financials

Sales 2024 * 1,572B 10.12B Sales 2025 * 1,669B 10.74B Capitalization 2,634B 16.95B
Net income 2024 * 13.41B 86.31M Net income 2025 * 133B 855M EV / Sales 2024 * 2 x
Net Debt 2024 * 503B 3.24B Net Debt 2025 * 448B 2.89B EV / Sales 2025 * 1.85 x
P/E ratio 2024 *
138 x
P/E ratio 2025 *
19.8 x
Employees 14,484
Yield 2024 *
4.81%
Yield 2025 *
5.05%
Free-Float 98.83%
More Fundamentals * Assessed data

Chart Astellas Pharma Inc.

Dynamic Chart

Latest news about Astellas Pharma Inc.

European Commission Approves Astellas Pharma Label Extension for Xtandi MT
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs CI
Lupin Launches Mirabegron Extended-Release Tablets in US MT
Japan Inc makes a renewed U.S. push as China fears mount RE
Middle East Tensions Blunt Asian Stock Markets Excepting China MT
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March MT
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment RE
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion RE
Astellas Pharma Inc. Provides Impairment Loss for Intangible Assets Guidance for the Fourth Quarter 2023 CI
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI
Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy MT
U.S. FDA Accepts Astellas? Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy CI
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China MT
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer CI
More news

Latest transcript on Astellas Pharma Inc.

Logo Astellas Pharma Inc.
Astellas Pharma Inc. - Special Call
More transcripts

Analyst Recommendations on Astellas Pharma Inc.

Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy MT
Jefferies Adjusts Astellas Pharma’s Price Target to 2,200 Yen From 2,400 Yen, Keeps at Buy MT
Jefferies Upgrades Astellas Pharma to Buy From Hold, Keeps Price Target at 2,400 Yen MT
Jefferies Adjusts Astellas Pharma's Price Target to 2,400 Yen From 2,300 Yen, Keeps at Buy MT
Jefferies Adjusts Astella Pharma’s Price Target to 2,300 Yen From 2,200 Yen, Keeps at Buy MT
More recommendations

Press releases Astellas Pharma Inc.

Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction against Lupin and Zydus Generic Versions of MyrbetriqTM AQ
U.S. FDA Accepts Astellas' Supplemental New Drug Application for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy AQ
Astellas VYLOY Approved in Japan for Treatment of Gastric Cancer AQ
Iveric Bio - Astellas Receives Permanent J-code for IZERVAY for Geographic Atrophy AQ
Astellas Receives Positive CHMP Opinion for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting AQ
More press releases

News in other languages on Astellas Pharma Inc.

MIDDAY BRIEFING - Unternehmen und Märkte
MÄRKTE ASIEN/Börsen stecken Eskalation im Nahen Osten gut weg
Aktien Asien/Pazifik: Eskalation im Nahen Osten drückt die Kurse - CSI legt zu
Bayer plant Zulassungsantrag für neues Mittel gegen Wechseljahrsbeschwerden
Sandoz-Aktien nach Jahreszahlen mit Abgaben
More news

Quotes and Performance

1 day-0.20%
1 week+0.03%
Current month-10.80%
1 month-11.34%
3 months-13.82%
6 months-24.99%
Current year-13.05%
More quotes

Highs and lows

1 week
1 462.50
Extreme 1462.5
1 509.00
1 month
1 426.00
Extreme 1426
1 696.50
Current year
1 426.00
Extreme 1426
1 801.50
1 year
1 426.00
Extreme 1426
2 360.50
3 years
1 426.00
Extreme 1426
2 360.50
5 years
1 375.00
Extreme 1375
2 360.50
10 years
1 108.00
Extreme 1108
2 360.50
More quotes

Managers and Directors - Astellas Pharma Inc.

Managers TitleAgeSince
Naoki Okamura CEO
 Chief Executive Officer 61 86-03-31
Kitamura Atsushi DFI
 Director of Finance/CFO 52 Oct. 31
Kenji Yasukawa CHM
 Chairman 63 86-03-31
Members of the board TitleAgeSince
Takashi Tanaka BRD
 Director/Board Member 67 21-05-31
Mamoru Sekiyama BRD
 Director/Board Member 74 17-05-31
Naoki Okamura CEO
 Chief Executive Officer 61 86-03-31
More insiders

ETFs positioned on Astellas Pharma Inc.

Name Weight AuM 1st Jan change Investor Rating
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY ETF Nomura NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY
11.47% 15 M€ +5.49%
NEXT FUNDS SOLACTIVE JAPAN ESG CORE INDEX ETF - JPY ETF NEXT FUNDS Solactive Japan ESG Core Index ETF - JPY
2.09% 251 M€ +13.17%
NEXT FUNDS TOPIX CORE 30 ETF - JPY ETF Next Funds TOPIX Core 30 ETF - JPY
2.01% 57 M€ +18.39%
GLOBAL X MSCI GOVERNANCE-QUALITY JAPAN ETF - JPY ETF Global X MSCI Governance-Quality Japan ETF - JPY
1.99% 11 M€ +11.05% -
More ETFs positioned on Astellas Pharma Inc.

Quotes

Date Price Change Volume
24-04-24 1,466 -0.20% 1 800 400
24-04-24 1,469 -1.51% 10,715,000
24-04-23 1,492 +1.05% 6,786,600
24-04-22 1,476 -0.30% 8,068,600
24-04-19 1,480 +1.02% 7,909,200

Delayed Quote Japan Exchange, April 24, 2024 at 08:35 pm EDT

More quotes

Company Profile

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Sector
Pharmaceuticals
Calendar
2024-04-24 - Q4 2023 Earnings Release
Related indices
Nikkei 225
More about the company

Income Statement Evolution

More financial data

Ratings for Astellas Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,469 JPY
Average target price
2,056 JPY
Spread / Average Target
+39.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ASTELLAS PHARMA INC. Stock Astellas Pharma Inc.
-13.05% 17.28B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.61% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.87% 570B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.24% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.49% 321B
ABBVIE INC. Stock AbbVie Inc.
+8.28% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+7.09% 217B
ROCHE HOLDING AG Stock Roche Holding AG
-9.12% 204B
NOVARTIS AG Stock Novartis AG
+5.01% 199B
PFIZER, INC. Stock Pfizer, Inc.
-8.75% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4503 Stock